Harvest One Cannabis Inc. (TSXV:HVT) (“Harvest One” or the “Company”) through its wholly owned subsidiary United Greeneries (“United Greeneries” or “UG”) is pleased to announce the launch of retail sales beginning February 2018;
Retail sales to commence February 2018
Over 325 kg of dried cannabis currently in stock for immediate sale
Initial import license for Satipharm’s Microgel Gelpell capsules received
United Greeneries as mainstage sponsor and exhibitor at Lift Conference Vancouver
Unique Product Line
Starting February 2018, United Greeneries will launch a new online retail platform for medical clients under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”). The initial offering will consist of two distinct cannabis brands, providing patients a wide range of different strains and cannabinoid profiles.
United Greeneries signature product line Captain’s Choice™ consists of blended, high-quality ground flowers. Captain’s Choice™ will be available in the varieties “Indica”, “Sativa” and “High-CBD”. United Greeneries’ controlled blending and grinding process allows for consistent product quality and will result in reduced production costs that the Company will be passing on to its customers.
The Company’s premium brand Royal High™ will feature prime quality cannabis flowers of selected varieties, initially consisting of Serious Kush, Great White Shark, Super Skunk, 8 Ball Kush and Chocolope. Several other varieties are currently in production.
Satipharm Gelpell Microgel Capsules
Photos accompanying this announcement are available at:
http://www.globenewswire.com/NewsRoom/AttachmentNg/d68f394d-7735-467a-961a-23ee29c062af
http://www.globenewswire.com/NewsRoom/AttachmentNg/c90439c5-3a60-47e5-bbd4-325b5c671e1a
The Company’s wholly owned Swiss subsidiary Satipharm AG has received an initial import license to Canada for its unique Gelpell Microgel capsules. The capsules are manufactured under pharmaceutical production standards in Switzerland and contain GMP produced CBD isolate with no detectable levels of other cannabinoids and are available in 10mg and 50mg presentations.
Satipharm’s products have undergone a successful Phase 1 Clinical Trial for safety and bioavailability and are currently utilized in two Phase 2 Clinical Trials for Refractory Pediatric Epilepsy and Pain and Spasticity in Multiple Sclerosis patients. The capsules are currently available for sale over the counter as a dietary supplement throughout pharmacies in the European Union and by special prescription in Australia.
Upon successful importation into Canada and passing of domestic quality control procedures, Satipharm’s Gelpell capsules will be added to United Greeneries’ ACMPR retail distribution. The Company estimates that it will be able to make this unique and industry leading product available to Canadian consumers during Q2 2018.
Marketing Strategy
United Greeneries will be the mainstage sponsor at the upcoming Lift Conference in Vancouver on January 13-14th. The Company is pleased to be hosting its first significant trade show exhibit to showcase our newly announced retail brands. We invite all Lift Vancouver participants to stop by and learn more about United Greeneries and our products.
About Harvest One Cannabis Inc. (TSXV:HVT)
Harvest One controls operations across the entire cannabis value chain through three business units, with Harvest One serving as the umbrella company over the Canadian Licensed Producer United Greeneries and the Swiss medical arm Satipharm AG. Each business is strategically located in favourable jurisdictions with supportive regulatory frameworks in place. United Greeneries has received a Canadian medicinal cannabis cultivation and sales license, positioning Harvest One as a unique global company with the capacity to commercially cultivate cannabis in a federally regulated environment.
For more information about Harvest One, please contact:
Colin Clancy
Investor Relations
+ 1 (877) 915-7934
cclancy@mmj.ca
Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. The forward-looking information contained in this press release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.
Neither TSX-V nor its Regulation Services Provider (as that term is defined in the policies of the TSX-V) accepts responsibility for the adequacy or accuracy of this release.
Click here to connect with Harvest One Cannabis Inc. (TSXV:HVT) for an Investor Presentation

Source: globenewswire.ca


Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Aurora Cannabis Inc. (NYSE: ACB) from February 13, 2020 through September 4, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Aurora Cannabis Inc. investors under the federal securities laws.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email info@pawarlawgroup.com for information on the class action.

Keep reading... Show less

The Israeli cannabis market is picking up with a new supply deal from a Canadian producer.

Also this week, new data showed sales of Canadian cannabis edible products may be stalling.

Keep reading... Show less

The Israeli cannabis market is picking up as a Canadian producer announced a new supply deal in the country.

Also this week it was shown the sales of Canadian cannabis edible products may be stalling, according to new data.

Keep reading... Show less

The Portnoy Law Firm advises investors that class action lawsuits have been filed on behalf of investors in the following publicly traded companies. Shareholders interested in taking an active role in these cases have until the deadlines indicated below to petition the court. There is no cost or obligation to you. See below for more information on these cases.

Credit Acceptance Corporation investors (NASDAQ: CACC); December 1, 2020 deadline, click here to join .

Keep reading... Show less
  • On November 19 , the Mexican Senate passed comprehensive adult-use cannabis legalization, moving Mexico towards becoming one of the few countries to legalize cannabis nationally
  • On March 31, 2020 , the Company entered into an agreement with Tecnologico de Monterrey , the leading university in Mexico , to educate physicians across Latin America , in advance of the impending regulations in Mexico
  • To date, close to 550 LatAm physicians have obtained their diploma accrediting completion of Khiron’s medical education program
  • The Company plans to deploy its ZereniaTM medical cannabis clinics and telehealth strategy in Mexico , building on the success of its vertical integration strategy in Colombia
  • Expanding the Zerenia clinic strategy will build on the Company’s Colombia knowledge and proven distribution capabilities, with rapid telehealth service adoption and over 5,600 medical cannabis scripts filled to date
  • Mexico represents one of the largest potential markets for medical cannabis in the world and is anticipated to reach $1.2bn USD by 2028 (Prohibition Partners).
  • Company to release Q3 2020 financials and host webcast on Tuesday, December 1st

Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe welcomes the passing of adult-use cannabis legislation by the Mexican Senate, which moves the country closer to a legalized cannabis market, and towards provision for medical cannabis products.  Khiron has had a presence in Mexico since 2018 and has been working with doctors and medical institutions to develop a deep understanding of the market.

Keep reading... Show less